Trials / Unknown
UnknownNCT04433845
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Sheppard Pratt Health System · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Psilocybin | Open-label |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2023-01-15
- Completion
- 2023-04-15
- First posted
- 2020-06-16
- Last updated
- 2022-10-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04433845. Inclusion in this directory is not an endorsement.